Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sagent and ICF sign development and supply collaboration agreement
Under the agreement, Itochu Chemical Frontier (ICF) will supply injectable products for which Sagent will obtain the US regulatory approval and market them in the US. Jeffrey Yordon,
Under the agreement, Itochu Chemical Frontier (ICF) will supply injectable products for which Sagent will obtain the US regulatory approval and market them in the US. Jeffrey Yordon,
The LBI embolectomy system consists of a 0.014” guide wire containing a three-dimensional fiber-based element used in combination with the previously cleared Xtract aspiration catheter. The expandable element
The company expects to report top-line results from this pivotal trial in November 2008. Ibuprofen is an analgesic that is sold in immediate-dose products as Advil and Motrin,
Additional participants include existing investors Aphelion Capital, California Technology Ventures and a group of accredited private individuals. Carter McNabb, managing director of River Cities Capital Funds has joined
The results from the bioequivalence study undertaken in September 2008 confirm that CPI 300 is bioequivalent to the reference product. Approval of the product is expected during the
This Phase II trial is a double-blind, placebo-controlled, parallel group study that is designed to assess the safety and efficacy of senicapoc, administered once a day for two
The facility will evaluate new processes to complement its current proprietary technologies – Meltrex, Xellex, NanoMorph and smartCrystals – that target the formulation of soluble complex pharmaceutical substances.
The patent claims are broad and include compositions of peptides for cancer immunotherapy as well as methods for inducing immune responses against tumor antigens in cancer patients. The
The Czech Republic office, located in Prague, is led by Libor Hubacek, country manager for Averion in the Czech Republic. Dr Hubacek will oversee monitoring and regulatory activities
Permacol, which joins the company’s line of products following the acquisition of Tissue Science Laboratories, is available in the US, Europe, Canada and Korea and will be registered